-去背.png){kind=logo}
啟弘生物科技股份有限公司
GMP Viral Vector
Manufacturing
End to End Total Solution Provider
Process Development
For Viral Vector
End to End Total Solution Provider
Biosafety Testing
GMP & GLP Compliance
End to End Total Solution Provider
-
AAV Manufacturing
AAV Manufacturing -
Lentivirus
Lentivirus -
Retrovirus
Retrovirus -
Adenovirus
Adenovirus
State-of-the-art manufacturing facility
To Make The World Better
TFBS Bioscience Inc. is a certified and leading GMP Viral Vector Contract Development and Manufacturing Organization in Asia-Pacific and the first specialist viral vector provider in Taiwan.
With the expertise in manufacturing and comprehensive testing services, we always stand by our clients and help them clarify their needs and what should be done through continuous communication.
We are proud of our total solution service and flexible scheduling that consistently supports our clients to get their products into the market as quickly as possible.
Testing
Cell Bank Characterization
The pivotal step to ensure the safety of the biopharmaceutical product is to perform characterization and biological safety testing of the cell line.
Studies of Viral Clearance
Manufacturers of biopharmaceutical products, such as blood products, monoclonal antibodies, recombinant proteins, and medical devices are required to demonstrate their process capability to remove or inactivate viruses.
Bulk Lot Release Testing
Every lot of biopharmaceutical production, requires a series of tests on both unprocessed and purified bulk material.
Preclinical and Clinical Samples Analysis
TFBS offers a flexible and solution-oriented laboratory services to support your needs for product-specific sample analysis at pre-clinical and clinical stages.
Assay Development in vivo and in vitro
TFBS provides a wide range of services to support assay development from early drug discovery, preclinical development, to clinical stage.
Animal Test
The pivotal step to ensure the safety of the biopharmaceutical product is to perform characterization and biological safety testing of the cell line.
News
啟弘生技竹北新廠正式啟用，台灣邁向國際病毒載體代工
啟弘生技竹北新廠正式啟用，台灣邁向國際病毒載體代工 台灣首家GMP等級病毒載體量產廠—啟弘生技（TFBS Bioscience Inc.）竹北新廠，正式開幕，標誌著台灣細胞與基因治療產業邁向商業化階段的重大里程碑，也彰顯了台灣生技產業CDMO逐漸在全球的供應鏈中佔據關鍵地位 2024-10-23 Minaris Regenerative Medicine and TFBS Announce Strategic Partnership to Advance Cell and Gene Therapy
Minaris Regenerative Medicine and TFBS Announce Strategic Partnership to Advance Cell and Gene Therapy Minaris Regenerative Medicine, LLC (Minaris) and TFBS Bioscience Inc. (TFBS) are pleased to announce a strategic partnership in cell and gene therapy (CGT) mainly in North America. This collaboration is designed to enhance their capabilities to drive industry innovation by providing the one-stop-shop solutions. 2024-10-02 President of TFBS Bioscience Inc. from Taiwan and Officials from National Taiwan University Visit President NAGATA
President of TFBS Bioscience Inc. from Taiwan and Officials from National Taiwan University Visit President NAGATA President of TFBS Bioscience Inc. from Taiwan and Officials from National Taiwan University Visit President NAGATA 2024-05-08 Be Partnered With TFBS
We envision that TFBS Bioscience will soon become a leading brand in Asia for biological analysis.
